Jack F M Wetzels

List of Publications by Year
in descending order

348	18,409	10389 72	18647 119
papers	citations	h-index	g-index

357	357	357	16428
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective. Nephrology Dialysis Transplantation, 2023, 38, 362-371.	0.7	3
2	Accuracy of Bioimpedance Spectroscopy in the Detection of Hydration Changes in Patients on Hemodialysis. , 2023, 33, 193-200.		1
3	Later Response to Corticosteroids in Adults With Primary Focal Segmental Glomerular Sclerosis Is Associated With Favorable Outcomes. Kidney International Reports, 2022, 7, 87-98.	0.8	6
4	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. Journal of the American Society of Nephrology: JASN, 2022, 33, 291-303.	6.1	10
5	Kidney tubule iron loading in experimental focal segmental glomerulosclerosis. Scientific Reports, 2022, 12, 1199.	3.3	6
6	The authors reply. Kidney International, 2022, 101, 187.	5.2	1
7	Referring patients with stable moderate to advanced chronic kidney disease back to primary care: a feasibility study. BJGP Open, 2022, , BJGPO.2021.0177.	1.8	0
8	Monoclonal gammopathy of renal significance presenting with cryoglobulinaemia type I associated severe thrombotic microangiopathy. CKJ: Clinical Kidney Journal, 2022, 15, 1425-1428.	2.9	2
9	Parietal epithelial cells maintain the epithelial cell continuum forming Bowman's space in focal segmental glomerulosclerosis. DMM Disease Models and Mechanisms, 2022, 15, .	2.4	4
10	Daratumumab for multidrug-resistant phospholipase-A2 receptorâ€“related membranous nephropathy. Kidney International, 2022, 101, 646-647.	5.2	8
11	Kidney Injury in Patients Treated with Immune Checkpoint Inhibitors Does Not Meet KDIGO-AKI Criteria. Kidney360, 2022, 3, 524-529.	2.1	2
12	Human pluripotent stem cell-derived kidney organoids for personalized congenital and idiopathic nephrotic syndrome modeling. Development (Cambridge), 2022, 149, .	2.5	16
13	Motile Cilia on Kidney Proximal Tubular Epithelial Cells Are Associated With Tubular Injury and Interstitial Fibrosis. Frontiers in Cell and Developmental Biology, 2022, 10, 765887.	3.7	3
14	MO168: Urinary Podocin Cell Count in Relation to Glomerular Damage Markers in Patients with Primary Nephrotic Syndrome. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
15	Eculizumab impairs killing of Neisseria meningitidis serogroup B in atypical hemolytic uremic syndrome patients vaccinated with MenB-4C. Kidney International, 2022, 101, 1293-1295.	5.2	2
16	Diagnosis and Treatment of Patients With FSGS/SRNS: A Delphi Survey. Kidney International Reports, 2022, , .	0.8	0
17	COVID-19 Vaccination in Patients With Membranous Nephropathy. Kidney International Reports, 2022, 7, 1922-1923.	0.8	3
18	Prognostic models for chronic kidney disease: a systematic review and external validation. Nephrology Dialysis Transplantation, 2021, 36, 1837-1850.	0.7	12

#	Article	IF	Citations
19	Novel in vitro assays to detect circulating permeability factor(s) in idiopathic focal segmental glomerulosclerosis. Nephrology Dialysis Transplantation, 2021, 36, 247-256.	0.7	12
20	The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney International, 2021, 99, 986-998.	5.2	104
21	HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. Kidney International, 2021, 99, 671-685.	5.2	24
22	Low plasma magnesium concentration and future abdominal aortic calcifications in moderate chronic kidney disease. BMC Nephrology, 2021, 22, 71.	1.8	3
23	Impact of diffusion, ultrafiltration, and posture on total body electrical resistance in patients on hemodialysis. Journal of Applied Physiology, 2021, 130, 318-324.	2.5	4
24	Functional tests to guide management in an adult with loss of function of type-1 angiotensin II receptor. Pediatric Nephrology, 2021, 36, 2731-2737.	1.7	0
25	Rituximab is preferable to cyclophosphamide for treatment of membranous nephropathy: CON. Kidney360, 2021, 2, 10.34067/KID.0001432021.	2.1	3
26	Anti-PLA2R1 Antibodies as Prognostic Biomarker in Membranous Nephropathy. Kidney International Reports, 2021, 6, 1677-1686.	0.8	17
27	Rituximab in Membranous Nephropathy. Kidney International Reports, 2021, 6, 881-893.	0.8	39
28	Therapeutic trials in adult FSGS: lessons learned and the road forward. Nature Reviews Nephrology, 2021, 17, 619-630.	9.6	53
29	The European Rare Kidney Disease Registry (ERKReg): objectives, design and initial results. Orphanet Journal of Rare Diseases, 2021, 16, 251.	2.7	26
30	Selective Binding of Heparin/Heparan Sulfate Oligosaccharides to Factor H and Factor H-Related Proteins: Therapeutic Potential for C3 Glomerulopathies. Frontiers in Immunology, 2021, 12, 676662.	4.8	4
31	Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Frontiers in Immunology, 2021, 12, 715704.	4.8	5
32	Establishment and characterization of a novel conditionally immortalized human parietal epithelial cell line. Experimental Cell Research, 2021, 405, 112712.	2.6	2
33	Membranous nephropathy. Nature Reviews Disease Primers, 2021, 7, 69.	30.5	167
34	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, S1-S276.	5.2	782
35	Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal. CKJ: Clinical Kidney Journal, 2021, 14, 1939-1945.	2.9	5
36	A Vasopressin-Induced Change in Prostaglandin Receptor Subtype Expression Explains the Differential Effect of PGE2 on AQP2 Expression. Frontiers in Physiology, 2021, 12, 787598.	2.8	2

#	Article	IF	Citations
37	Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. Nephrology Dialysis Transplantation, 2020, 35, 1002-1009.	0.7	66
38	The multifaceted role of iron in renal health and disease. Nature Reviews Nephrology, 2020, 16, 77-98.	9.6	167
39	The zinc fingers and homeoboxes 2 protein ZHX2 and its interacting proteins regulate upstream pathways in podocyte diseases. Kidney International, 2020, 97, 753-764.	5.2	9
40	Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?. Autoimmunity Reviews, 2020, 19, 102671.	5.8	37
41	Conversion of Urine Proteinâ€“Creatinine Ratio or Urine Dipstick Protein to Urine Albuminâ€“Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis. Annals of Internal Medicine, 2020, 173, 426-435.	3.9	144
42	Worldwide Disparity in the Relation Between CKD Prevalence and Kidney Failure Risk. Kidney International Reports, 2020, 5, 2284-2291.	0.8	9
43	Authorâ€™s Reply to Liu et al.: â€œPharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumabâ€• Clinical Pharmacokinetics, 2020, 59, 1645-1646.	3.5	0
44	Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease. Kidney International, 2020, 98, 989-998.	5.2	36
45	Inhibition of mTOR delayed but could not prevent experimental collapsing focal segmental glomerulosclerosis. Scientific Reports, 2020, 10, 8580.	3.3	3
46	Proteomic Analysis Identifies Distinct Glomerular Extracellular Matrix in Collapsing Focal Segmental Glomerulosclerosis. Journal of the American Society of Nephrology: JASN, 2020, 31, 1883-1904.	6.1	37
47	The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nature Communications, 2020, 11, 1600.	12.8	120
48	The complement component C5 is not responsible for the alternative pathway activity in rabbit erythrocyte hemolytic assays during eculizumab treatment. Cellular and Molecular Immunology, 2020, 17, 653-655.	10.5	6
49	Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient. Frontiers in Immunology, 2020, 11, 612706.	4.8	9
50	Standardized reporting of monoclonal immunoglobulinâ€“associated renal diseases: recommendations from a Mayo Clinic/Renal Pathology Society Working Group. Kidney International, 2020, 98, 310-313.	5.2	7
51	Management and treatment of glomerular diseases (part 1): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Nephrology (Saint-Petersburg), 2020, 24, 22-41.	0.4	10
52	Treatment-resistant nephrotic syndrome in dense deposit disease: complement-mediated glomerular capillary wall injury?. Pediatric Nephrology, 2020, 35, 1791-1795.	1.7	1
53	Glomerular Outgrowth as an Ex Vivo Assay to Analyze Pathways Involved in Parietal Epithelial Cell Activation. Journal of Visualized Experiments, 2020, , .	0.3	0
54	Serum albumin measurement in nephrology: room for improvement. Nephrology Dialysis Transplantation, 2020, , .	0.7	3

#	Article	IF	Citations
55	Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data. Journal of the American Society of Nephrology: JASN, 2019, 30, 1746-1755.	6.1	109
56	Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation. Journal of the American Society of Nephrology: JASN, 2019, 30, 1756-1769.	6.1	71
57	Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease. Gastroenterology, 2019, 157, 481-491.e7.	1.3	42
58	The authors reply. Kidney International, 2019, 96, 249.	5.2	1
59	Genetic Identification of Two Novel Loci Associated with Steroid-Sensitive Nephrotic Syndrome. Journal of the American Society of Nephrology: JASN, 2019, 30, 1375-1384.	6.1	40
60	Five non-mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes phenotype adult patients with m.3243A>G mutation after kidney transplantation: follow-up and review of the literature. CKJ: Clinical Kidney Journal, 2019, 12, 840-846.	2.9	13
61	SaO003USE OF THIAZIDE DIURETICS DOES NOT WORSEN DISEASE PROGRESSION IN ADPKD. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
62	FP641PERFORMANCE AND PITFALLS OF THE FRESENIUSÂ® BODY COMPOSITION MONITOR FOR WATER BALANCE MANAGEMENT IN PATIENTS ON HEMODIALYSIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
63	Unraveling Hepcidin Plasma Protein Binding: Evidence from Peritoneal Equilibration Testing. Pharmaceuticals, 2019, 12, 123.	3.8	8
64	The anti-PLA2R antibody in membranous nephropathy: what we know and what remains aÂdecade after its discovery. Kidney International, 2019, 96, 1292-1302.	5.2	97
65	NMR and MS urinary metabolic phenotyping in kidney diseases is fit-for-purpose in the presence of a protease inhibitor. Molecular Omics, 2019, 15, 39-49.	2.8	5
66	FP196NOVEL ELISA FOR THSD7A AUTOANTIBODIES IN MEMBRANOUS NEPHROPATHY. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
67	Urinary Tissue Inhibitor ofÂMetalloproteinases-2 and Insulin-Like Growth Factorâ€“Binding Protein 7 Do Not Correlate With Disease Severity in ADPKD Patients. Kidney International Reports, 2019, 4, 833-841.	0.8	3
68	Predicting kidney failure from longitudinal kidney function trajectory: A comparison of models. PLoS ONE, 2019, 14, e0216559.	2.5	5
69	The bias between different albumin assays may affect clinical decision-making. Kidney International, 2019, 95, 1514-1517.	5.2	26
70	Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. Kidney International, 2019, 95, 666-679.	5.2	68
71	Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clinical Pharmacokinetics, 2019, 58, 859-874.	3.5	82
72	Nephrotic Syndrome With Mutations in NPHS2: The Role of R229Q and Implications for Genetic Counseling. American Journal of Kidney Diseases, 2019, 73, 400-403.	1.9	13

#	Article	IF	Citations
73	Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatric Nephrology, 2019, 34, 2261-2277.	1.7	60
74	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 268-280.	5.2	198
75	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 281-295.	5.2	135
76	Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes and Endocrinology,the, 2019, 7, 115-127.	11.4	199
77	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes and Endocrinology,the, 2019, 7, 128-139.	11.4	223
78	Neuropeptide Y and chronic kidney disease progression: a cohort study. Nephrology Dialysis Transplantation, 2018, 33, 1805-1812.	0.7	18
79	CD44 is required for the pathogenesis of experimental crescentic glomerulonephritis and collapsing focal segmental glomerulosclerosis. Kidney International, 2018, 93, 626-642.	5.2	52
80	Immunological remission in PLA2R-antibodyâ€“associated membranous nephropathy: cyclophosphamide versus rituximab. Kidney International, 2018, 93, 1016-1017.	5.2	50
81	Interleukin-6 is essential for glomerular immunoglobulin A deposition and the development of renal pathology in Cd37-deficientÂmice. Kidney International, 2018, 93, 1356-1366.	5.2	25
82	Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. European Heart Journal, 2018, 39, 1535-1542.	2.2	218
83	Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome. Nephrology Dialysis Transplantation, 2018, 33, 635-645.	0.7	36
84	Antibodies Against M-Type Phospholipase Receptor and Prediction of Outcome in Membranous Nephropathy: We are Not There Yet. American Journal of Nephrology, 2018, 48, 434-437.	3.1	2
85	Urine Acidification After Ammonium Chloride. American Journal of Kidney Diseases, 2018, 72, 909-911.	1.9	2
86	The authors reply. Kidney International, 2018, 94, 830.	5.2	0
87	Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease. JAMA - Journal of the American Medical Association, 2018, 320, 2010.	7.4	78
88	SaO018FACTOR D INHIBITION WITH ACH-4471 TO REDUCE COMPLEMENT ALTERNATIVE PATHWAY HYPERACTIVITY AND PROTEINURIA IN C3 GLOMERULOPATHY: PRELIMINARY PROOF OF CONCEPT DATA. Nephrology Dialysis Transplantation, 2018, 33, i322-i322.	0.7	1
89	What Patients with Mild-to-Moderate Kidney Disease Know, Think, and Feel about Their Disease: An In-Depth Interview Study. Journal of the American Board of Family Medicine, 2018, 31, 570-577.	1.5	9
90	Effects of sildenafil, metformin, and simvastatin on ADH-independent urine concentration in healthy volunteers. Physiological Reports, 2018, 6, e13665.	1.7	13

#	Article	IF	Citations
91	The Calcium-Dependent Protease Calpain-1 Links TRPC6 Activity to Podocyte Injury. Journal of the American Society of Nephrology: JASN, 2018, 29, 2099-2109.	6.1	44
92	General practitionersâ€™ perspectives on management of early-stage chronic kidney disease: a focus group study. BMC Family Practice, 2018, 19, 81.	2.9	18
93	Lifetime risk of renal replacement therapy in Europe: a population-based study using data from the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 2017, 32, gfw392.	0.7	13
94	Abdominal aortic calcification in patients with CKD. Journal of Nephrology, 2017, 30, 109-118.	2.0	59
95	New advances in the treatment of glomerular disease. Nature Reviews Nephrology, 2017, 13, 65-66.	9.6	3
96	Copeptin, a surrogate marker for arginine vasopressin, is associated with disease severity and progression in IgA nephropathy patients. Nephrology Dialysis Transplantation, 2017, 32, gfw391.	0.7	7
97	Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study. Drug Safety, 2017, 40, 153-167.	3.2	16
98	The Clinical Course of Minimal Change Nephrotic Syndrome With Onset in Adulthood or Late Adolescence: A Case Series. American Journal of Kidney Diseases, 2017, 69, 637-646.	1.9	39
99	Clinical Relevance of Differences in Glomerular Filtration Rate Estimations in Frail Older People by Creatinine- vs. Cystatin C-Based Formulae. Drugs and Aging, 2017, 34, 445-452.	2.7	8
100	Adherence to chronic kidney disease guidelines in primary care patients is associated with comorbidity. Family Practice, 2017, 34, 459-466.	1.9	13
101	Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 2729-2737.	6.1	125
102	Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome. Nephrology Dialysis Transplantation, 2017, 32, i115-i122.	0.7	20
103	Lithium-induced NDI: acetazolamide reduces polyuria but does not improve urine concentrating ability. American Journal of Physiology - Renal Physiology, 2017, 313, F669-F676.	2.7	14
104	Use of the Furosemide Fludrocortisone Test to Clinically Assess Distal Tubular Acidification. American Journal of Kidney Diseases, 2017, 70, 589-591.	1.9	6
105	Urinary Excretion of Î± 1 -Microglobulin Does Not Predict Graft Loss in Stable Kidney Transplant Recipients. American Journal of Kidney Diseases, 2017, 70, 151.	1.9	2
106	Development and Pretesting of a Questionnaire to Assess Patient Experiences and Satisfaction with Medications (PESaM Questionnaire). Patient, 2017, 10, 629-642.	2.7	14
107	Prostaglandins in thiazide-induced hyponatraemia: do they hold water?. Nature Reviews Nephrology, 2017, 13, 665-666.	9.6	1
108	The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease. American Journal of Nephrology, 2017, 46, 239-248.	3.1	15

#	Article	IF	Citations
109	Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data. Lancet Diabetes and Endocrinology,the, 2017, 5, 718-728.	11.4	110
110	Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series. American Journal of Kidney Diseases, 2017, 70, 770-777.	1.9	46
111	A Novel Hypokalemic-Alkalotic Salt-Losing Tubulopathy in Patients with CLDN10 Mutations. Journal of the American Society of Nephrology: JASN, 2017, 28, 3118-3128.	6.1	52
112	Disposition and clinical implications of protein-bound uremic toxins. Clinical Science, 2017, 131, 1631-1647.	4.3	39
113	Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort. Pediatric Nephrology, 2017, 32, 139-150.	1.7	71
114	Reference values of renal tubular function tests are dependent on age and kidney function. Physiological Reports, 2017, 5, e13542.	1.7	3
115	Web-based consultation between general practitioners and nephrologists: a cluster randomized controlled trial. Family Practice, 2017, 34, 430-436.	1.9	19
116	Differential diagnosis of thrombotic microangiopathy in nephrology. BMC Nephrology, 2017, 18, 324.	1.8	3
117	Uremic Solutes in Chronic Kidney Disease and Their Role in Progression. PLoS ONE, 2016, 11, e0168117.	2.5	20
118	Kidney Weight in Living and Postmortal Kidney Donation. Transplantation, 2016, 100, e1-e2.	1.0	1
119	Kidney Dysfunction Increases Mortality and Incident Events after Young Stroke: The FUTURE Study. Cerebrovascular Diseases, 2016, 42, 224-231.	1.7	15
120	Renal Handling of Circulating and Renal-Synthesized Hepcidin and Its Protective Effects against Hemoglobinâ€“Mediated Kidney Injury. Journal of the American Society of Nephrology: JASN, 2016, 27, 2720-2732.	6.1	50
121	Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy?. Kidney International, 2016, 89, 981-983.	5.2	23
122	Pharmacokinetics and pharmacodynamics of eculizumab in individualized treatment of atypical hemolytic uremic syndrome. Immunobiology, 2016, 221, 1141.	1.9	1
123	Pharmacological treatment of primary membranous nephropathy in 2016. Expert Review of Clinical Pharmacology, 2016, 9, 1463-1478.	3.1	23
124	Drug therapy management in patients with renal impairment: how to use creatinine-based formulas in clinical practice. European Journal of Clinical Pharmacology, 2016, 72, 1433-1439.	1.9	20
125	Minimal change disease and idiopathic FSGS: manifestations of the same disease. Nature Reviews Nephrology, 2016, 12, 768-776.	9.6	125
126	Quality of chronic kidney disease management in primary care: a retrospective study. Scandinavian Journal of Primary Health Care, 2016, 34, 73-80.	1.5	27

#	Article	IF	Citations
127	What is the relationship between renal function and visit-to-visit blood pressure variability in primary care? Retrospective cohort study from routinely collected healthcare data. BMJ Open, 2016, 6, e010702.	1.9	9
128	Kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as prognostic markers in idiopathic membranous nephropathy. Annals of Clinical Biochemistry, 2016, 53, 51-57.	1.6	7
129	Thiazide Responsiveness Testing in Patients With Renal Magnesium Wasting and Correlation With Genetic Analysis: A Diagnostic Test Study. American Journal of Kidney Diseases, 2016, 68, 168-170.	1.9	11
130	1,25-Vitamin D3 Deficiency Induces Albuminuria. American Journal of Pathology, 2016, 186, 794-804.	3.8	20
131	Acetazolamide Attenuates Lithiumâ€“Induced Nephrogenic Diabetes Insipidus. Journal of the American Society of Nephrology: JASN, 2016, 27, 2082-2091.	6.1	43
132	Hepatocyte Nuclear Factor 1Î²â€“Associated Kidney Disease. Journal of the American Society of Nephrology: JASN, 2016, 27, 345-353.	6.1	117
133	Central arteriovenous anastomosis and hypertension. Lancet, The, 2015, 386, 1821.	13.7	2
134	Rituximab can induce remission of nephrotic syndrome in the absence of peripheral B-cells. Nephrology, 2015, 20, 667-668.	1.6	2
135	Increased expression of lysosome membrane protein 2 in glomeruli of patients with idiopathic membranous nephropathy. Proteomics, 2015, 15, 3722-3730.	2.2	28
136	Individualizing Pharmacotherapy in Patients with Renal Impairment: The Validity of the Modification of Diet in Renal Disease Formula in Specific Patient Populations with a Glomerular Filtration Rate below 60 Ml/Min. A Systematic Review. PLoS ONE, 2015, 10, e0116403.	2.5	10
137	Differential Expression of Specific Dermatan Sulfate Domains in Renal Pathology. PLoS ONE, 2015, 10, e0134946.	2.5	9
138	Elevated Urinary Connective Tissue Growth Factor in Diabetic Nephropathy Is Caused by Local Production and Tubular Dysfunction. Journal of Diabetes Research, 2015, 2015, 1-11.	2.3	18
139	Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up. Kidney International, 2015, 87, 1263-1264.	5.2	59
140	Proximal tubular efflux transporters involved in renal excretion of p-cresyl sulfate and p-cresyl glucuronide: Implications for chronic kidney disease pathophysiology. Toxicology in Vitro, 2015, 29, 1868-1877.	2.4	51
141	Discontinuation of Eculizumab Maintenance Treatment for Atypical Hemolytic Uremic Syndrome. American Journal of Kidney Diseases, 2015, 65, 342.	1.9	35
142	Urinary biomarkers after donor nephrectomy. Transplant International, 2015, 28, 544-552.	1.6	6
143	Maintenance of steroid-free remission in nephrotic syndrome. Nature Reviews Nephrology, 2015, 11, 569-570.	9.6	1
144	Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clinical Immunology, 2015, 160, 237-243.	3.2	42

#	Article	IF	Citations
145	Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients. Journal of Nephrology, 2015, 28, 477-484.	2.0	14
146	Prevalence of Apparent Therapy-Resistant Hypertension and Its Effect on Outcome in Patients With Chronic Kidney Disease. Hypertension, 2015, 66, 998-1005.	2.7	39
147	A European multicentre and open-label controlled randomized trial to evaluate the efficacy ofSequential treatment with TAcrolimusâ€“Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study. CKJ: Clinical Kidney Journal, 2015, 8, 503-510.	2.9	47
148	Estimation of Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease. American Journal of Kidney Diseases, 2015, 66, 792-801.	1.9	36
149	Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial. Liver International, 2015, 35, 1607-1614.	3.9	43
150	Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study. PLoS ONE, 2015, 10, e0142033.	2.5	23
151	TRPC6 Single Nucleotide Polymorphisms and Progression of Idiopathic Membranous Nephropathy. PLoS ONE, 2014, 9, e102065.	2.5	6
152	The Biobank of Nephrological Diseases in the Netherlands cohort: the String of Pearls Initiative collaboration on chronic kidney disease in the university medical centers in the Netherlands. Nephrology Dialysis Transplantation, 2014, 29, 1145-1150.	0.7	18
153	The search goes on: suPAR is not the elusive FSGS factor. Nature Reviews Nephrology, 2014, 10, 431-432.	9.6	14
154	Serum suPAR concentrations in patients with focal segmental glomerulosclerosis with end-stage renal disease. Kidney International, 2014, 85, 711.	5.2	8
155	Cancer Risk after Cyclophosphamide Treatment in Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1066-1073.	4.5	80
156	Time-averaged level of fibroblast growth factor-23 and clinical events in chronic kidney disease. Nephrology Dialysis Transplantation, 2014, 29, 88-97.	0.7	37
157	Hydrochlorothiazide attenuates lithium-induced nephrogenic diabetes insipidus independently of the sodium-chloride cotransporter. American Journal of Physiology - Renal Physiology, 2014, 306, F525-F533.	2.7	38
158	Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future. Nephrology Dialysis Transplantation, 2014, 29, 2207-2216.	0.7	82
159	Nurse Practitioner Care Improves Renal Outcome in Patients with CKD. Journal of the American Society of Nephrology: JASN, 2014, 25, 390-398.	6.1	90
160	Longitudinal trends in thyroid function in relation to iodine intake: ongoing changes of thyroid function despite adequate current iodine status. European Journal of Endocrinology, 2014, 170, 49-54.	3.7	21
161	The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney International, 2014, 85, 636-640.	5.2	106
162	Measurement of serum suPAR is not ready for clinical use. Nature Reviews Nephrology, 2014, 10, 610-610.	9.6	2

#	Article	IF	Citations
163	Association of Anti-PLA2R Antibodies with Outcomes after Immunosuppressive Therapy in Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1386-1392.	4.5	152
164	Detection of Activated Parietal Epithelial Cells on the Glomerular Tuft Distinguishes Early Focal Segmental Glomerulosclerosis from Minimal Change Disease. American Journal of Pathology, 2014, 184, 3239-3248.	3.8	81
165	Phospholipase A2 Receptor Antibodies in Membranous Nephropathy: Unresolved Issues. Journal of the American Society of Nephrology: JASN, 2014, 25, 1137-1139.	6.1	31
166	Remote ischemic preconditioning to reduce contrast-induced nephropathy: study protocol for a randomized controlled trial. Trials, 2014, 15, 119.	1.6	9
167	Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab. Nephrology Dialysis Transplantation, 2014, 29, iv131-iv141.	0.7	65
168	Rationale and Design of the DIPAK 1 Study: A Randomized Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in Autosomal Dominant Polycystic Kidney Disease. American Journal of Kidney Diseases, 2014, 63, 446-455.	1.9	59
169	Glucose Specifically Regulates TRPC6 Expression in the Podocyte in an AngII-Dependent Manner. American Journal of Pathology, 2014, 184, 1715-1726.	3.8	62
170	B Cell Suppression in Primary Glomerular Disease. Advances in Chronic Kidney Disease, 2014, 21, 166-181.	1.4	7
171	Long-Term Outcomes in Idiopathic Membranous Nephropathy Using a Restrictive Treatment Strategy. Journal of the American Society of Nephrology: JASN, 2014, 25, 150-158.	6.1	70
172	Long-Term Treatment with Tenofovir: Prevalence of Kidney Tubular Dysfunction and Its Association with Tenofovir Plasma Concentration. Antiviral Therapy, 2014, 19, 765-771.	1.0	52
173	Proximal tubular cells contain a phenotypically distinct, scattered cell population involved in tubular regeneration. Journal of Pathology, 2013, 229, 645-659.	4.5	188
174	Treatment of idiopathic membranous nephropathy. Nature Reviews Nephrology, 2013, 9, 443-458.	9.6	104
175	Tubular reabsorption and local production of urine hepcidin-25. BMC Nephrology, 2013, 14, 70.	1.8	27
176	A retrospective study of focal segmental glomerulosclerosis: clinical criteria can identify patients at high risk for recurrent disease after first renal transplantation. BMC Nephrology, 2013, 14, 47.	1.8	46
177	Serum suPAR in patients with FSGS: trash or treasure?. Pediatric Nephrology, 2013, 28, 1041-1048.	1.7	71
178	Vitamin D Down-Regulates TRPC6 Expression in Podocyte Injury and Proteinuric Glomerular Disease. American Journal of Pathology, 2013, 182, 1196-1204.	3.8	44
179	Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Clinica Chimica Acta, 2013, 421, 213-218.	1.1	117
180	Immunosuppression for membranous nephropathy. Lancet, The, 2013, 381, 2162.	13.7	1

#	Article	IF	Citations
181	Early Development of Hyperparathyroidism Due to Loss ofPTHTranscriptional Repression in Patients With HNF1Î² Mutations?. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4089-4096.	3.6	26
182	Active proteases in nephrotic plasma lead to a podocinâ€dependent phosphorylation of <scp>VASP</scp> in podocytes via protease activated receptorâ€1. Journal of Pathology, 2013, 229, 660-671.	4.5	62
183	Extending Prednisolone Treatment Does Not Reduce Relapses in Childhood Nephrotic Syndrome. Journal of the American Society of Nephrology: JASN, 2013, 24, 149-159.	6.1	113
184	Impact on cardiovascular risk follow-up from a shift to the CKD-EPI formula for eGFR reporting: a cross-sectional population-based primary care study. BMJ Open, 2013, 3, e003631.	1.9	3
185	Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrology Dialysis Transplantation, 2013, 28, 3062-3071.	0.7	67
186	Validation of the kidney failure risk equation in European CKD patients. Nephrology Dialysis Transplantation, 2013, 28, 1773-1779.	0.7	75
187	Phospholipase A2 Receptor (PLA2R1) Sequence Variants in Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2013, 24, 677-683.	6.1	108
188	Initial Implementation of a Web-Based Consultation Process for Patients With Chronic Kidney Disease. Annals of Family Medicine, 2013, 11, 151-156.	1.9	53
189	Demeclocycline attenuates hyponatremia by reducing aquaporin-2 expression in the renal inner medulla. American Journal of Physiology - Renal Physiology, 2013, 305, F1705-F1718.	2.7	20
190	New TRPC6 gain-of-function mutation in a non-consanguineous Dutch family with late-onset focal segmental glomerulosclerosis. Nephrology Dialysis Transplantation, 2013, 28, 1830-1838.	0.7	47
191	Urinary Connective Tissue Growth Factor Is Associated with Human Renal Allograft Fibrogenesis. Transplantation, 2013, 96, 494-500.	1.0	12
192	Effect of shared care on blood pressure in patients with chronic kidney disease: a cluster randomised controlled trial. British Journal of General Practice, 2013, 63, e798-e806.	1.4	30
193	Optimized Metabolomic Approach to Identify Uremic Solutes in Plasma of Stage 3â€“4 Chronic Kidney Disease Patients. PLoS ONE, 2013, 8, e71199.	2.5	55
194	Prognostic Value of Risk Score and Urinary Markers in Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1242-1248.	4.5	41
195	Multifactorial intervention with nurse practitioners does not change cardiovascular outcomes in patients with chronic kidney disease. Kidney International, 2012, 82, 710-717.	5.2	77
196	Genetic causes of focal segmental glomerulosclerosis: implications for clinical practice. Nephrology Dialysis Transplantation, 2012, 27, 882-890.	0.7	109
197	Serum-soluble urokinase receptor concentration in primary FSGS. Kidney International, 2012, 81, 1043-1044.	5.2	67
198	Antiphospholipase A2 Receptor Antibody Titer and Subclass in Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 1735-1743.	6.1	270

#	Article	IF	Citations
199	Epidemiology of Contrast Materialâ€“induced Nephropathy in the Era of Hydration. Radiology, 2012, 263, 706-713.	7.3	77
200	Subtotal Ablation of Parietal Epithelial Cells Induces Crescent Formation. Journal of the American Society of Nephrology: JASN, 2012, 23, 629-640.	6.1	61
201	Age and Association of Kidney Measures With Mortality and End-stage Renal Disease. JAMA - Journal of the American Medical Association, 2012, 308, 2349.	7.4	493
202	Chronic kidney disease and mortality risk among older patients with type 2 diabetes mellitus (ZODIAC-24). Age and Ageing, 2012, 41, 345-350.	1.6	12
203	Quantifying the benefit of early living-donor renal transplantation with a simulation model of the Dutch renal replacement therapy population. Nephrology Dialysis Transplantation, 2012, 27, 429-434.	0.7	9
204	Management of patients with membranous nephropathy. Nephrology Dialysis Transplantation, 2012, 27, 6-9.	0.7	92
205	Urinary heparanase activity in patients with Type 1 and Type 2 diabetes. Nephrology Dialysis Transplantation, 2012, 27, 2853-2861.	0.7	40
206	Lithium reduces aquaporin-2 transcription independent of prostaglandins. American Journal of Physiology - Cell Physiology, 2012, 302, C131-C140.	4.6	41
207	In mpkCCD cells, long-term regulation of aquaporin-2 by vasopressin occurs independent of protein kinase A and CREB but may involve Epac. American Journal of Physiology - Renal Physiology, 2012, 302, F1395-F1401.	2.7	48
208	Clinical evaluation of analytical variations in serum creatinine measurements: why laboratories should abandon Jaffe techniques. BMC Nephrology, 2012, 13, 133.	1.8	69
209	Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease. BMC Nephrology, 2012, 13, 17.	1.8	16
210	Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: An analysis of the MASTERPLAN cohort. BMC Nephrology, 2012, 13, 20.	1.8	42
211	Differences between hospitals in attainment of parathyroid hormone treatment targets in chronic kidney disease do not reflect differences in quality of care. BMC Nephrology, 2012, 13, 82.	1.8	2
212	Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA. Nephrology Dialysis Transplantation, 2012, 27, 3923-3929.	0.7	20
213	Hepcidin-25 in Chronic Hemodialysis Patients Is Related to Residual Kidney Function and Not to Treatment with Erythropoiesis Stimulating Agents. PLoS ONE, 2012, 7, e39783.	2.5	47
214	Effect of GFR on Plasma N-Terminal Connective Tissue Growth Factor (CTGF) Concentrations. American Journal of Kidney Diseases, 2012, 59, 619-627.	1.9	21
215	Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood, 2011, 117, e218-e225.	1.4	246
216	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney International, 2011, 79, 1331-1340.	5.2	609

#	Article	IF	Citations
217	Angiotensin II Contributes to Podocyte Injury by Increasing TRPC6 Expression via an NFAT-Mediated Positive Feedback Signaling Pathway. American Journal of Pathology, 2011, 179, 1719-1732.	3.8	180
218	High urinary excretion of kidney injury molecule-1 is an independent predictor of end-stage renal disease in patients with IgA nephropathy. Nephrology Dialysis Transplantation, 2011, 26, 3581-3588.	0.7	63
219	Estimated glomerular filtration rate in the nephrotic syndrome. Nephrology Dialysis Transplantation, 2011, 26, 550-556.	0.7	18
220	Low-Molecular-Weight Proteins as Prognostic Markers in Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2846-2853.	4.5	65
221	Anti-Phospholipase A2 Receptor Antibodies Correlate with Clinical Status in Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1286-1291.	4.5	320
222	Parietal Epithelial Cells Participate in the Formation of Sclerotic Lesions in Focal Segmental Glomerulosclerosis. Journal of the American Society of Nephrology: JASN, 2011, 22, 1262-1274.	6.1	186
223	Introduction of the CKD-EPI equation to estimate glomerular filtration rate in a Caucasian population. Nephrology Dialysis Transplantation, 2011, 26, 3176-3181.	0.7	87
224	Hypotonicity-induced Reduction of Aquaporin-2 Transcription in mpkCCD Cells Is Independent of the Tonicity Responsive Element, Vasopressin, and cAMP. Journal of Biological Chemistry, 2011, 286, 13002-13010.	3.4	18
225	Immunosuppressive treatment of focal segmental glomerulosclerosis: lessons from a randomized controlled trial. Kidney International, 2011, 80, 798-801.	5.2	19
226	Risk HLA-DQA1 and PLA₂R1 Alleles in Idiopathic Membranous Nephropathy. New England Journal of Medicine, 2011, 364, 616-626.	27.0	442
227	The Clinician and Estimation of Glomerular Filtration Rate by Creatinine-based Formulas. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 937-950.	4.5	88
228	Uremic Toxins Inhibit Transport by Breast Cancer Resistance Protein and Multidrug Resistance Protein 4 at Clinically Relevant Concentrations. PLoS ONE, 2011, 6, e18438.	2.5	113
229	Deficiency of Either P-Glycoprotein or Breast Cancer Resistance Protein Protect against Acute Kidney Injury. Cell Transplantation, 2010, 19, 1195-1208.	2.5	10
230	Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention. Journal of Nuclear Medicine, 2010, 51, 1049-1058.	5.0	245
231	Quality of care in patients with chronic kidney disease is determined by hospital specific factors. Nephrology Dialysis Transplantation, 2010, 25, 3647-3654.	0.7	15
232	Expression of sialidase and dystroglycan in human glomerular diseases. Nephrology Dialysis Transplantation, 2010, 25, 478-484.	0.7	13
233	Renal proximal tubular dysfunction is a major determinant of urinary connective tissue growth factor excretion. American Journal of Physiology - Renal Physiology, 2010, 298, F1457-F1464.	2.7	25
234	Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial. Nephrology Dialysis Transplantation, 2010, 25, 129-136.	0.7	55

#	Article	IF	Citations
235	Association of Variants at UMOD with Chronic Kidney Disease and Kidney Stonesâ€"Role of Age and Comorbid Diseases. PLoS Genetics, 2010, 6, e1001039.	3.5	166
236	Alkylating agents in membranous nephropathy: efficacy proven beyond doubt. Nephrology Dialysis Transplantation, 2010, 25, 1760-1766.	0.7	42
237	Blood Pressure Control in Type 2 Diabetes. New England Journal of Medicine, 2010, 363, 695-697.	27.0	3
238	Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrology Dialysis Transplantation, 2010, 25, 848-853.	0.7	99
239	Immunochemical and Mass-Spectrometryâ€"Based Serum Hepcidin Assays for Iron Metabolism Disorders. Clinical Chemistry, 2010, 56, 1570-1579.	3.2	190
240	Comparison of three methods for isolation of urinary microvesicles to identify biomarkers of nephrotic syndrome. Kidney International, 2010, 78, 810-816.	5.2	228
241	Estimating Glomerular Filtration Rate. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 899-906.	4.5	138
242	Renal Progenitor Cells Contribute to Hyperplastic Lesions of Podocytopathies and Crescentic Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2009, 20, 2593-2603.	6.1	173
243	Tracing the Origin of Glomerular Extracapillary Lesions from Parietal Epithelial Cells. Journal of the American Society of Nephrology: JASN, 2009, 20, 2604-2615.	6.1	218
244	Amiloride blocks lithium entry through the sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus. Kidney International, 2009, 76, 44-53.	5.2	104
245	Cystatin C levels are unaltered in patients with diabetes mellitus and normal renal function. Kidney International, 2009, 76, 462.	5.2	4
246	Long-Term Outcome of Biopsy-Proven, Frequently Relapsing Minimal-Change Nephrotic Syndrome in Children. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1593-1600.	4.5	117
247	Cardiovascular and Noncardiovascular Mortality Among Patients Starting Dialysis. JAMA - Journal of the American Medical Association, 2009, 302, 1782.	7.4	584
248	Hepcidin Levels in Acute Kidney Injury Following Cardiopulmonary Bypass Grafting. American Journal of Kidney Diseases, 2009, 54, 979.	1.9	5
249	Hepcidin levels in patients with renal disease. Kidney International, 2009, 76, 680.	5.2	4
250	Renal outcomes in the ONTARGET study. Lancet, The, 2008, 372, 2020.	13.7	3
251	Rituximab for plasma exchange-dependent recurrent focal segmental glomerulosclerosis after renal transplantation. CKJ: Clinical Kidney Journal, 2008, 1, 85-88.	2.9	1
252	Introduction of a cyclophosphamide-based treatment strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: A nationwide survey in the Netherlands. Nephrology Dialysis Transplantation, 2008, 23, 3534-3538.	0.7	15

#	Article	IF	Citations
253	Urinary albumin:total protein ratioâ€"a new diagnostic tool to differentiate glomerular from nonglomerular hematuria. Nature Clinical Practice Nephrology, 2008, 4, 590-591.	2.0	0
254	Beta-2-microglobulin is superior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic membranous nephropathy. Nephrology Dialysis Transplantation, 2008, 23, 2546-2551.	0.7	48
255	Reducing Renal Uptake of Radiolabeled Peptides Using Albumin Fragments. Journal of Nuclear Medicine, 2008, 49, 1506-1511.	5.0	78
256	Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. Kidney International, 2008, 74, 1568-1576.	5.2	130
257	Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy. Nephrology Dialysis Transplantation, 2008, 23, 3160-3165.	0.7	37
258	Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?. Nephrology Dialysis Transplantation, 2008, 23, 2450-2453.	0.7	71
259	MASTERPLAN: study of the role of nurse practitioners in a multifactorial intervention to reduce cardiovascular risk in chronic kidney disease patients. Journal of Nephrology, 2008, 21, 261-7.	2.0	37
260	Cyclophosphamide plus steroids for membranous nephropathy with nephrotic syndrome: long-term outcomes. Nature Clinical Practice Nephrology, 2007, 3, 534-535.	2.0	0
261	Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome?. Nephrology Dialysis Transplantation, 2007, 22, 2100-2102.	0.7	47
262	Focal segmental glomerulosclerosis is not a sufficient predictor of renal outcome in patients with membranous nephropathy. Nephrology Dialysis Transplantation, 2007, 22, 2201-2207.	0.7	19
263	Letter by Wetzels Regarding Article, â€œRenal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): A Randomized Comparison of 3 Preventive Strategiesâ€• Circulation, 2007, 116, e310; author reply e311.	1.6	1
264	Adult and paediatric patients with minimal change nephrotic syndrome show no major alterations in glomerular expression of sulphated heparan sulphate domains. Nephrology Dialysis Transplantation, 2007, 22, 2886-2893.	0.7	8
265	Pathological variants of focal segmental glomerulosclerosis in an adult Dutch population epidemiology and outcome. Nephrology Dialysis Transplantation, 2007, 23, 186-192.	0.7	77
266	Membranous Nephropathy in the Older Adult. Drugs and Aging, 2007, 24, 717-732.	2.7	27
267	Biomarker discovery with SELDI-TOF MS in human urine associated with early renal injury: evaluation with computational analytical tools. Nephrology Dialysis Transplantation, 2007, 22, 2932-2943.	0.7	37
268	Long-Term Outcome After Cyclophosphamide Treatment in Children With Steroid-Dependent and Frequently Relapsing Minimal Change Nephrotic Syndrome. American Journal of Kidney Diseases, 2007, 49, 592-597.	1.9	54
269	Mycophenolate Mofetil in Idiopathic Membranous Nephropathy: A Clinical Trial With Comparison to a Historic Control Group Treated With Cyclophosphamide. American Journal of Kidney Diseases, 2007, 50, 248-256.	1.9	82
270	Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. Design of The MASTERPLAN Study [ISRCTN73187232]. Trials, 2006, 7, 8.	1.6	12

#	Article	IF	Citations
271	Effect of creatinine assay standardization on the performance of Cockcroftâ€“Gault and MDRD formula in predicting GFR. Nephrology Dialysis Transplantation, 2006, 21, 2998-2999.	0.7	19
272	Angiotensin converting enzyme inhibition prevents development of collapsing focal segmental glomerulosclerosis in Thy-1.1 transgenic mice. Nephrology Dialysis Transplantation, 2006, 21, 3087-3097.	0.7	12
273	Treatment-related changes in urinary excretion of high and low molecular weight proteins in patients with idiopathic membranous nephropathy and renal insufficiency. Nephrology Dialysis Transplantation, 2006, 21, 389-396.	0.7	12
274	Expression and Effect of Inhibition of Aminopeptidase-A during Nephrogenesis. Journal of Histochemistry and Cytochemistry, 2006, 54, 253-262.	2.5	8
275	Macroalbuminuria Is a Better Risk Marker than Low Estimated GFR to Identify Individuals at Risk for Accelerated GFR Loss in Population Screening. Journal of the American Society of Nephrology: JASN, 2006, 17, 2582-2590.	6.1	176
276	Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. Journal of Nuclear Medicine, 2006, 47, 432-6.	5.0	62
277	Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. Journal of Nuclear Medicine, 2006, 47, 528-33.	5.0	63
278	The parietal epithelial cell is crucially involved in human idiopathic focal segmental glomerulosclerosis11See editorial by Schwartz, p. 1894.. Kidney International, 2005, 68, 1562-1572.	5.2	104
279	Screening for microalbuminuria. Kidney International, 2005, 68, 1899-1900.	5.2	0
280	Idiopathic Membranous Nephropathy: Outline and Rationale of a Treatment Strategy. American Journal of Kidney Diseases, 2005, 46, 1012-1029.	1.9	122
281	New Insights Into the Pathogenesis and the Therapy of Recurrent Focal Glomerulosclerosis. American Journal of Transplantation, 2005, 5, 2594-2594.	4.7	2
282	Small increases in the urinary excretion of glutathione S-transferase A1 and P1 after cardiac surgery are not associated with clinically relevant renal injury. Intensive Care Medicine, 2005, 31, 664-667.	8.2	31
283	Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrology Dialysis Transplantation, 2005, 20, 707-711.	0.7	118
284	Angiotensin II Type 1â€“Receptor Activating Antibodies in Renal-Allograft Rejection. New England Journal of Medicine, 2005, 352, 2027-2028.	27.0	17
285	Urinary Excretion of Î²2-Microglobulin and IgG Predict Prognosis in Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2005, 16, 169-174.	6.1	117
286	Iron chelators do not reduce cold-induced cell injury in the isolated perfused rat kidney model. Nephrology Dialysis Transplantation, 2005, 20, 2646-2653.	0.7	6
287	Rationale and design of the MASTERPLAN study: Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. Journal of Nephrology, 2005, 18, 30-4.	2.0	19
288	Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. Nephrology Dialysis Transplantation, 2004, 19, 1142-1148.	0.7	83

#	Article	IF	Citations
289	The Parietal Epithelial Cell: A Key Player in the Pathogenesis of Focal Segmental Glomerulosclerosis in Thy-1.1 Transgenic Mice. Journal of the American Society of Nephrology: JASN, 2004, 15, 928-939.	6.1	78
290	Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity. Nephrology Dialysis Transplantation, 2004, 19, 2036-2043.	0.7	20
291	Serum ferritin levels are increased in patients with glomerular diseases and proteinuria. Nephrology Dialysis Transplantation, 2004, 19, 2754-2760.	0.7	34
292	Plasma exchange improves graft survival in patients with recurrent focal glomerulosclerosis after renal transplantation. Transplant International, 2004, 17, 151-157.	1.6	54
293	The fractional excretion of soluble interleukin-2 receptor-?? is an excellent predictor of the interleukin-2 receptor-?? status after treatment with daclizumab. Transplantation, 2004, 77, 281-286.	1.0	8
294	Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrology Dialysis Transplantation, 2004, 19, 2852-2857.	0.7	58
295	Plasma exchange improves graft survival in patients with recurrent focal glomerulosclerosis after renal transplantation. Transplant International, 2004, 17, 151-157.	1.6	26
296	Decreased renal excretion of soluble interleukin-2 receptor Î± after treatment with daclizumab. Kidney International, 2003, 64, 697-703.	5.2	9
297	Hypothermia causes a marked injury to rat proximal tubular cells that is aggravated by all currently used preservation solutions. Cryobiology, 2003, 47, 82-91.	0.7	40
298	Podocyte Changes after Induction of Acute Albuminuria in Mice by Anti-Aminopeptidase A mAb. Nephron Experimental Nephrology, 2003, 94, e85-e93.	2.2	17
299	Abnormal Vitamin D Metabolism and Loss of Bone Mass after Renal Transplantation. Nephron Clinical Practice, 2003, 93, c21-c28.	2.3	27
300	Epitope Mapping of Monoclonal Antibodies Directed to Aminopeptidase A and Their Relevance for Albuminuria in Mice. Nephron Experimental Nephrology, 2003, 94, e25-e34.	2.2	2
301	Podocyte changes upon induction of albuminuria in Thy-1.1 transgenic mice. Nephrology Dialysis Transplantation, 2003, 18, 2524-2533.	0.7	30
302	Treatment of recurrent focal glomerulosclerosis after renal transplantation: is prednisone essential to maintain a sustained remission?. Transplantation, 2003, 75, 1080-1081.	1.0	4
303	Response to â€œproteinuria in normal cadaver kidney donorsâ€. Transplantation, 2003, 76, 439-440.	1.0	1
304	Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections1. Transplantation, 2003, 76, 821-826.	1.0	85
305	Outcome of renal transplantation in patients with systemic lupus erythematosus. Transplant International, 2003, 16, 411-418.	1.6	15
306	Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. Nephrology Dialysis Transplantation, 2002, 17, 1909-1913.	0.7	200

#	Article	IF	Citations
307	Treatment with Vitamin D and Calcium Reduces Bone Loss after Renal Transplantation: A Randomized Study. Journal of the American Society of Nephrology: JASN, 2002, 13, 1608-1614.	6.1	132
308	Atrial natriuretic peptideâ€“induced microalbuminuria is associated with endothelial dysfunction in noncomplicated type 1 diabetes patients. American Journal of Kidney Diseases, 2002, 40, 9-15.	1.9	19
309	Nephrotic syndrome associated with anti-tumor necrosis factor ? therapy in a patient with rheumatoid arthritis: Comment on the article by Charles et al. Arthritis and Rheumatism, 2002, 46, 1691-1693.	6.7	6
310	Antibody-induced albuminuria and accelerated focal glomerulosclerosis in the Thy-1.1 transgenic mouse. Kidney International, 2002, 62, 116-126.	5.2	27
311	The gelatin-derived plasma substitute Gelofusine causes low-molecular-weight proteinuria by decreasing tubular protein reabsorption. Journal of Critical Care, 2001, 16, 115-120.	2.2	37
312	Familial nephropathy differing from minimal change nephropathy and focal glomerulosclerosis. Kidney International, 2001, 59, 693-701.	5.2	28
313	Albuminuria in Mice after Injection of Antibodies against Aminopeptidase A. Journal of the American Society of Nephrology: JASN, 2001, 12, 2711-2720.	6.1	13
314	Dissociation between urine osmolality and urinary excretion of aquaporinâ€2 in healthy volunteers. Nephrology Dialysis Transplantation, 2000, 15, 1155-1161.	0.7	34
315	Primary Epsteinâ€“Barr virus infection and recurrent type I membranoproliferative glomerulonephritis after renal transplantation. Nephrology Dialysis Transplantation, 2000, 15, 1235-1237.	0.7	7
316	The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation. Nephrology Dialysis Transplantation, 2000, 15, 711-714.	0.7	97
317	Type I membranoproliferative glomerulonephritis in a renal allograft: A recurrence induced by a cytomegalovirus infection?. American Journal of Kidney Diseases, 2000, 35, e6.1-e6.7.	1.9	19
318	Urinary Excretion of Glutathione S Transferases Alpha and Pi in Patients with Proteinuria: Reflection of the Site of Tubular Injury. Nephron, 2000, 85, 120-126.	1.8	85
319	Influence of Albumin Infusion on the Urinary Excretion of Î²₂-Microglobulin in Patients with Proteinuria. Nephron, 1999, 81, 329-333.	1.8	9
320	Quantitative Determination of Low and High Molecular Weight Proteins in Human Urine: Influence of Temperature and Storage Time. Clinical Chemistry, 1999, 45, 430-432.	3.2	32
321	Recurrent focal glomerulosclerosis: natural course and treatment with plasma exchange. Nephrology Dialysis Transplantation, 1999, 14, 2650-2656.	0.7	72
322	Elevated Skeletal Muscle Blood Flow in Noncomplicated Type 1 Diabetes Mellitus. Hypertension, 1999, 34, 1080-1085.	2.7	51
323	Induction of albuminuria in mice: Synergistic effect of two monoclonal antibodies directed to different domains of aminopeptidase A. Kidney International, 1999, 55, 1335-1347.	5.2	19
324	Transcapillary escape rate of albumin is increased and related to haemodynamic changes in normo-albuminuric type 1 diabetic patients. Journal of Hypertension, 1999, 17, 1911-1916.	0.5	25

#	Article	IF	Citations
325	Hypoxia decreases calcium influx into rat proximal tubules. Kidney International, 1998, 53, 703-708.	5.2	10
326	Antihypertensive treatment of patients with proteinuric renal diseases: Risks or benefits of calcium channel blockers?. Kidney International, 1998, 53, 1559-1573.	5.2	116
327	Effects of renal cytoprotective agents on erythrocyte membrane stability. Life Sciences, 1998, 63, 975-983.	4.3	6
328	Influence of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor antagonism on renal sodium and water handling and albuminuria during infusion of atrial natriuretic factor into healthy volunteers. Journal of Hypertension, 1998, 16, 245-250.	0.5	13
329	COLD PRESERVATION OF ISOLATED RABBIT PROXIMAL TUBULES INDUCES RADICAL-MEDIATED CELL INJURY1. Transplantation, 1998, 65, 625-632.	1.0	42
330	RECURRENCE OF TYPE I MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS AFTER RENAL TRANSPLANTATION. Transplantation, 1997, 63, 1628-1633.	1.0	76
331	Atheroembolic Disease in a Female Patient. Circulation, 1997, 96, 700-700.	1.6	2
332	Induced Alterations in Calcium Uptake Rate in Normoxic Rat Proximal Tubules. Renal Failure, 1995, 17, 503-515.	2.1	2
333	Familial glomerulonephritis characterized by massive deposits of fibronectin. American Journal of Kidney Diseases, 1995, 25, 781-791.	1.9	58
334	Acute Effects of Nifedipine in Renal Transplant Recipients Treated With Cyclosporine or Azathioprine. American Journal of Kidney Diseases, 1994, 24, 838-845.	1.9	8
335	New technique to assess hypoxia-induced cell injury in individual isolated renal tubules. Kidney International, 1993, 43, 464-469.	5.2	19
336	Angiotensin Converting Enzyme Inhibition Does Not Prevent the Natriuretic Effect of Felodipine. Journal of Cardiovascular Pharmacology, 1993, 21, 471-477.	1.9	5
337	Prevention and attenuation of acute renal failure. Current Opinion in Nephrology and Hypertension, 1992, 1, 133-140.	2.0	2
338	Calcium Channel Blockers: Protective Effects in Ischemic Acute Renal Failure. Renal Failure, 1992, 14, 327-332.	2.1	12
339	Is increased erythrocyte sodium-lithium countertransport a useful marker for diabetic nephropathy?. Kidney International, 1992, 41, 862-871.	5.2	30
340	Acute phosphate depletion and in vitro rat proximal tubule injury: Protection by glycine and acidosis. Kidney International, 1992, 41, 1494-1500.	5.2	27
341	Evidence for renal vasodilation in pre-dialysis patients during correction of anemia by erythropoietin. Kidney International, 1992, 41, 384-387.	5.2	12
342	Drug-Induced Nephrotoxicity Aetiology, Clinical Features and Management. Drug Safety, 1991, 6, 131-147.	3.2	72

#	Article	IF	Citations
343	Evaluation of a closed perfusion chamber for single cell fluorescence measurements. Journal of Immunological Methods, 1991, 141, 289-291.	1.4	4
344	Cimetidine improves the reliability of creatinine as a marker of glomerular filtration. Kidney International, 1991, 40, 1171-1176.	5.2	108
345	Prednisolone can increase glomerular permeability to proteins in nephrotic syndrome. Kidney International, 1988, 33, 1169-1174.	5.2	12
346	The Natriuretic Effect of the Dihydropyridine Calcium Antagonist Felodipine. Journal of Cardiovascular Pharmacology, 1987, 10, S154-161.	1.9	7
347	The Natriuretic Effect of the Dihydropyridine Calcium Antagonist Felodipine. Journal of Cardiovascular Pharmacology, 1987, 10, S154-161.	1.9	15
348	Prednisone-Induced Fluctuations of Proteinuria in Patients with a Nephrotic Syndrome. Nephron, 1986, 44, 344-350.	1.8	17